# Coming soon HCI-014 PDX

Catalogue number: 162083

Sub-type: Images:

### Contributor

Inventor: Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose Institute: The University of Utah Research Foundation

Images:

### **Tool details**

### \*FOR RESEARCH USE ONLY

Name: Coming soon HCI-014 PDX

Alternate name:

Class:

Conjugate:

Cancer Tools.org **Description:** Please register your interest through the enquiry button (quote not currently available) Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. Sample collected from pleural effusion of Caucasian female, age 60 at time of collection with a primary diagnosis of ILC; 2009. Patient had no prior history of smoking, and experienced clinical metastasis to the bone. Patient had undergone radiation therapy to left hip (2009) and had systemic treatment of zoledronic acid 2009-2010; doxirubicin, paclitaxel 2009; gemcitabine, carboplatin 2010 prior to sample collection. Patient and PDX characteristics were as follows - ER status: negative, PR status: negative, HER2 status: negative. PDX information:PAM50 subtype is HER2-enriched and shows metastasis to lymph node and lung.

Purpose: Parental cell: Organism: Tissue: Model:

Gender: Female

Isotype: Reactivity: Selectivity:

Host:

Immunogen:

**Immunogen UNIPROT ID:** 

Sequence:

**Growth properties:** 

Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogenindependent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Formulation: Frozen explant from the xenografted tumour

Recommended controls: **Bacterial resistance:** Selectable markers:

**Additional notes:** Additional Information on PDX establishment: Target alternate names: Cancer Tools.org

Molecular weight:

lc50:

# **Applications**

**Application:** 

**Application notes:** 

### Handling

Format:

Concentration: Passage number: **Growth medium:** 

Temperature: **Atmosphere:** 

Volume:

Storage medium: Storage buffer: Storage conditions: Shipping conditions:

### **Related tools**

Related tools:

## References

References:

